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Objectives: Previous research suggests that LDL particle number (LDL-P) may be a better tool than LDL
cholesterol (LDL-C) to guide LDL-lowering therapy. Using real-world data, this study has two objectives:
[1] to determine the incidence of CHD across LDL-P thresholds; and [2] to compare CHD/stroke events
among patients achieving comparably low LDL-P or LDL-C levels.
Methods: A claims analysis was conducted among high-risk patients identiﬁed from the HealthCore
Integrated Research DatabaseSM. The impact of LDL levels on risk was compared across cohorts who
achieved LDL-P <1000 nmol/L or LDL-C <100 mg/dL. Cohorts were matched to balance demographic and
comorbidity differences.
Results: Among 15,569 patients with LDL-P measurements, the risk of a CHD event increased by 4% for
each 100 nmol/L increase in LDL-P level (HR 1.04; 95% CI 1.02e1.05, p < .0001). The comparative analysis
included 2,094 matched patients with 12 months of follow-up, 1,242 with 24 months and 705 with
36 months. At all time periods, patients undergoing LDL-P measurement were more likely to receive
intensive lipid-lowering therapy and had a lower risk of CHD/stroke than those in the LDL-C cohort (HR:
0.76; 95% CI: 0.61e0.96; at 12 months).
Conclusions: In this real-world sample of commercially insured patients, higher LDL-P levels were
associated with increased CHD risk. Moreover, high-risk patients who achieved LDL-P <1000 nmol/L
received more aggressive lipid-lowering therapy than patients achieving LDL-C <100 mg/dL, and these
differences in lipids and therapeutic management were associated with a reduction in CHD/stroke events
over 12, 24 and 36 months follow-up.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
The causal link between increased quantity of LDL and the
development of CHD is well established [1e4]. Elevated LDL
quantity accelerates the development of atherosclerotic disease
and the longer the exposure to elevated LDL, the greater the risk ofL-C, low-density lipoprotein
number; MESA, multiethnic
DM, type 2 diabetes mellitus.




Ireland Ltd. This is an open accesssuch cardiovascular events as myocardial infarction, ischemic
stroke, and coronary mortality. Lowering LDL quantity is a key
strategy for reducing CHD risk recommended by treatment guide-
lines which were developed on the basis of strong evidence from
primary and secondary prevention trials with statins [1e5].
LDL-C has served as the principal biomarker for LDL quantity for
many years. An alternative measure of LDL quantity is LDL particle
number (LDL-P), determined directly by nuclear magnetic reso-
nance spectroscopy or estimated from apolipoprotein B concen-
trations [6,7]. LDL-C is a measure of the cholesterol content of LDL
particles which can vary signiﬁcantly between individuals and in
response to drug and lifestyle interventions; therefore, LDL-C levels
do not always accurately reﬂect a patient's LDL-related risk [8e10].
This is especially true for patients with T2DM, metabolic syndrome,
or hypertriglyceridemia who often have LDL particles that arearticle under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-
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from multiple epidemiological studies have demonstrated that
LDL-P better predicts cardiovascular events than LDL-C concen-
trations, particularly in patients whose LDL-P and LDL-C levels are
discordant [11e13].
Recognizing that measurements of LDL-P may provide a better
indicator of CHD risk, several expert panels and guidelines advocate
the use of LDL-P as a target of therapy in the management of
appropriate at-risk patients [14e17]. Most recently, the American
Association of Clinical Endocrinologist's (AACE) Comprehensive
Diabetes Management Algorithm 2013 Consensus Statement
speciﬁed a LDL-P target of <1000 nmol/L for patients with T2DM at
high risk of CVD [14]. Additional real-world evidence is needed to
demonstrate that clinical management aided by access to LDL-P
information leads to improvement in cardiovascular outcomes.
To this end, we used a national sample of commercially insured
high-risk patients to evaluate two objectives: First, to determine
the frequency of CHD events across different LDL-P thresholds; and
second, to compare baseline characteristics and CHD/stroke out-
comes in high-risk patients achieving comparably low levels of
LDL-C and LDL-P. To our knowledge this is the ﬁrst large-scale, real-
world study investigating the potential beneﬁt of LDL-P as an aid to
patient management to prevent CHD/stroke events.
2. Methods
2.1. Data source and patient identiﬁcation
Administrative claims were obtained from the HealthCore In-
tegrated Research DatabaseSM (HIRDSM). The HIRD contains eligi-
bility, medical, and pharmacy claims for approximately 36 million
members of Blue Cross and Blue Shield health plans geographically
dispersed across the United States. Laboratory results (including
LDL-P measurements) which had been provided to physicians and
patients in the course of their normal medical care were also ob-
tained from the HIRD and augmented with additional LDL-P and
lipid panel data from LipoScience, Inc. Researchers only had access
to a limited data set and procedures were in compliance with the
1996 Health Insurance Portability and Accountability Act. The study
was approved by a central Institutional Review Board.
The analysis included adults (18 years of age) who had at least
one electronic LDL-P result (CPT 83704 or LOINC 54434-6) between
January 1, 2006 and September 30, 2012. Patients had to be enrolled
in a commercial health plan or Medicare Advantage to be included
in the study. Inclusion of LDL-P results provided by LipoScience, Inc.
increased the total available sample size by approximately 13%,
relative to the sample based solely on HIRD data.
2.2. Study design
The study design was comprised of two parts: Part 1 (CHD Inci-
dence), an observational cohort study comparing CHD risk among
patients with varying levels of LDL-P to informoptimal LDL-P targets,
and Part 2 (LDL-P vs. LDL-C Comparison), an observational cohort
study comparing CHD, stroke, and combined CHD/stroke risk be-
tween patients achieving pre-speciﬁed targets for LDL-C and LDL-P.
2.2.1. Part 1: assessment of CHD incidence by LDL-P
To assess the frequency of CHD events across LDL-P thresholds,
all patients with at least 1 LDL-P result were included. The index
date was deﬁned as the date of the most recently available LDL-P
result preceding a CHD event, or the end of the follow-up period
for patients who did not have a CHD event. All patients were
required to have at least 6 months of continuous medical and
pharmacy health plan enrollment prior to the index date toestablish baseline medication use and comorbidities. Patients were
followed until either the end of continuous health plan eligibility,
the end of the available data stream, or death (as recorded in the
Social Security Administration's Death Master File), whichever
occurred ﬁrst. Patients were also required to have at least 1 LDL-C
result pre-index. Lastly, the analysis focused on high-risk patients
with prior CHD or CHD risk-equivalents. High-risk was determined
based on the occurrence of at least 1 of the following events at any
time prior to the index date: (1) established CHD, stroke, TIA, or
peripheral arterial disease as identiﬁed by relevant International
Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation (ICD-9-
CM) diagnosis codes or a prescription ﬁll for clopidogrel; (2) at least
2 medical claims for diabetes mellitus (ICD-9-CM code 250.xx) or at
least 1 prescription ﬁll for an antidiabetic medication.
2.2.2. Part 2: comparative effectiveness analysis of LDL-P vs. LDL-C
on CHD/stroke risk
Given the consistent observation from a number of prospective
epidemiologic cohorts that LDL-P better predicts cardiovascular
outcomes than LDL-C even after rigorous adjustment for estab-
lished cardiovascular risk factors [11e13], we evaluated whether
high-risk patients who achieved LDL-P <1000 nmol/L experienced
lower cardiovascular event rates compared to patients who achieve
LDL-C <100 mg/dL (based on NCEP ATP III guidelines [1]). Patients
who had at least 1 LDL-P level <1000 at any point in the study
periodwere placed in the LDL-P target cohort; patients with at least
1 LDL-C result <100 but no LDL-Pmeasurements were placed in the
LDL-C target cohort. The index date for both cohorts was set as the
earliest observed test date where the target laboratory value was
achieved. All patients were again required to have at least 6 months
of continuous medical and pharmacy health plan enrollment prior
to the index date. Patients in the LDL-P target cohort were also
required to have at least 1 LDL-C result of any value on or during the
6 months pre-index date. High-risk patients were identiﬁed using
the same method as used in Part 1 for the CHD incidence assess-
ment. Within the LDL-P and LDL-C target cohorts, patients were
grouped into 12-month, 24-month and 36-month cohorts based on
the length of their available follow-up period (at least 12, 24, or 36
months); patients with longer follow-up were allowed to be in
multiple cohorts (for example, a patient with 25 months of follow-
up was included in the 12 and 24 month cohorts). Within each
cohort outcomes were assessed over the available follow-up time
(for example, CHD events were assessed over 12months in the LDL-
P and LDL-C cohorts with at least 12 months of follow-up data).
2.3. Outcome measures
Both parts of this study captured patient characteristics such as
demographics, comorbidities (including the QuaneCharlson Co-
morbidity Index (QCI) score [18]), medication utilization, and lab-
oratory values (e.g. lipid panels, LDL-P, and HDL-P) during the
baseline period, deﬁned as the 6 months before the index date.
Part 1 (CHD Incidence) focused on CHD events as the primary
outcome measure based on NCEP ATP III guidelines [1]. To
encompass a broader spectrum of potentially affected outcomes,
Part 2 (LDL-P vs. LDL-C Comparison) looked at CHD and stroke risk,
as well as a combined CHD/stroke endpoint. CHD (which included
myocardial infarction (MI), angina, and revascularization) and
stroke were identiﬁed by ICD-9-CM diagnoses and procedural
codes and Common Procedural Terminology (CPT) codes on med-
ical claims. To ensure that only acute events were captured, the
analysis focused on CHD and stroke events identiﬁed frommedical
claims in an inpatient or emergency room setting.
In Part 1 (CHD Incidence), outcomes were assessed during the
entire follow-up period; in Part 2 (LDL-P vs. LDL-C Comparison), all
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months), except for laboratory values where a ±90-day window
was used at the end of each follow-up period.
2.4. Statistical analysis
All analyses were performed using SAS 9.2 (SAS Institute Inc.,
Cary, NC). Statistical signiﬁcance was deﬁned as a p-value <0.05.
2.4.1. Part 1: assessment of CHD incidence by LDL-P
Baseline characteristics were described for all high-risk patients
with and without post-index CHD events. Descriptive analyses
included means (standard deviation [SD]) and relative frequencies
for continuous and categorical variables, respectively. Continuous
outcomes were compared using independent t-tests or Wilcoxon
rank sum tests (based on the distribution of each outcome). Cate-
gorical outcomes were compared using c2 tests. Cox proportional
hazards models were used to compare CHD event incidence across
LDL-P thresholds (<700 nmol/L, <1000 nmol/L, <1300 nmol/L,
<1600 nmol/L, and <2000 nmol/L) after adjusting for baseline de-
mographics, comorbidities, and LDL-C level. A separate Cox PH
model using LDL-P as a continuous covariate was also created.
2.4.2. Part 2: comparative effectiveness analysis of LDL-P vs. LDL-C
on CHD/stroke risk
Baseline patient characteristics were compared between the
LDL-C and LDL-P cohorts separately at 12-month, 24-month and
36-month follow-up periods, using the same statistical methods as
in Part 1. Stringent 1:1 propensity score matching was used to
balance the baseline demographic and comorbidity differences
between each of the LDL-P and LDL-C cohorts deﬁned by the length
of the follow-up period [19e21]. Differences in treatment patterns
and lipid values were left intact. Balance after matching was
assessed using unpaired statistical tests as well as standardized
differences. Thus, three separate matched LDL-P and LDL-C cohorts
were identiﬁed.
CHD and stroke event risk was assessed as the percentage of
patients experiencing at least 1 event as well as the mean number
of events per patient. Unadjusted Cox PH models were used to
compare CHD/stroke event incidence between LDL-C and LDL-P
cohorts for each follow-up period. KaplaneMeier curves for the
combined CHD/stroke endpoint were created for each matched
subsample.Fig. 1. Distribution of LDL-P and LDL-C e Histogram of LDL-P and LDL-C3. Results
3.1. Part 1: assessment of CHD incidence by LDL-P
3.1.1. Patient characteristics
A total of 57,025 patients met the inclusion and exclusion
criteria for the study; of these, 15,569 had prior CHD or CHD risk-
equivalents and were included in the analysis (refer to Appendix
Table 1 for additional patient selection information). Among
high-risk patients, 1,291 (8.3%) had one or more CHD events during
the follow-up period (Appendix Table 2). Patients with a post-index
CHD event tended to be older (61 years vs. 56 years, p < .0001) men
(65% vs. 55%, p < .0001), compared with those who did not have a
post-index CHD event. At baseline, signiﬁcantly higher proportions
of patients with post-index CHD events had comorbid hypertension
(71.5% vs. 54.7%, p < .0001) and established CHD (69.6% vs. 30.0%,
p < .0001) than those without post-index CHD events, although a
higher percentage of patients without post-index CHD had diabetes
(77.5% vs. 57.1%, p < .0001).
At baseline, the mean LDL-P level was 1443 nmol/L for patients
without a post-index CHD event, and 1426 nmol/L for those with a
post-index CHD event (p ¼ .237). Approximately 15% of the total
study population had LDL-P levels below a threshold of 1000 nmol/
L, while more than 50% of patients had LDL-C levels <100 mg/dL
(Fig. 1). Differences in lipid values across the two cohorts were
statistically signiﬁcant but clinically similar.
3.1.2. CHD event risk
The risk of a CHD event increased approximately 4% for each
100 nmol/L increase in LDL-P level (hazard ratio 1.04; 95% conﬁ-
dence interval 1.02e1.05, p < .0001). Point estimates for CHD risk
also increasedmonotonically across several pre-deﬁned thresholds,
with statistically signiﬁcant increases observed for LDL-P levels
exceeding 1300 nmol/L, 1600 nmol/L, and 2000 nmol/L (Fig. 2).
3.2. Part 2: comparative effectiveness analysis of LDL-P vs. LDL-C on
CHD/stroke risk
As described above, three separate pairs of matched cohorts
were created to examine outcomes in patients with at least 12, 24,
and 36 months of follow-up data. Patient characteristics and lab-
oratory values at baseline are presented below in detail for the 12
month sample; outcomes are presented for all three cohortvalues at baseline (Part 1: Assessment of CHD incidence by LDL-P).
Fig. 2. Risk for future CHD events by LDL-P e Hazard Ratios (HRs) for future CHD events across LDL-P thresholds adjusted for baseline demographics, comorbidities, and LDL-C.
Median follow-up was 10.1 months. Sample sizes indicate the number of patients with LDL-P levels at or above the designated thresholds. (Part 1: Assessment of CHD incidence by
LDL-P).
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samples is available in the Appendix.
3.2.1. Patient characteristics
A total of 195,202 patients were included in the 12 month
sample, 2,094 in the LDL-P target cohort and 193,108 in the LDL-C
target cohort. The two groups differed signiﬁcantly in several
baseline characteristics including age, region of residence, and
health plan enrollment; certain comorbidities including hyperlip-
idemia and diabetes; as well as laboratory values and medication
utilization. After 1:1 propensity score matching, there were no
signiﬁcant differences between the groups in demographic char-
acteristics or baseline comorbidities. Table 1 describes baseline
characteristics after matching for patients with 12-months follow-
up. For both cohorts, mean age was 56 years, 57% of patients were
male, >60% residing in the southern US, with a high prevalence of
hypertension, hyperlipidemia and diabetes. Between-group differ-
ences in laboratory values and medication utilization were
expressly retained. In particular, a higher percentage of patients in
the LDL-P cohort received higher potency statin therapy compared
to patients in the LDL-C cohort. The baseline characteristics of
matched cohorts with 24-months and 36-months follow-up are
presented in Appendix Table 4.
3.2.2. Laboratory values
Patients in the LDL-C cohort had higher levels of LDL-C, total
cholesterol, triglycerides, and non-HDL-C, and lower levels of HDL-
C, compared with those in the LDL-P cohort both at baseline and at
12 months follow up (Appendix Table 5). Mean (SD) LDL-P on index
date was 858 (106). Mean (SD) LDL-C at baseline was 73 (21) in the
LDL-P cohort and 79 (15) in the LDL-C cohort. Most laboratory
values were higher at 12 months follow-up than at baseline, and
these changes over time were greater in the LDL-C cohort. Results
for the 24 month and 36 month subsamples were similar
(Appendix Table 6).
3.2.3. CHD/Stroke event risk
Compared with patients in the LDL-C cohort, fewer patients in
the LDL-P cohort had a CHD event, stroke, or combined CHD/strokeevents at 12 months, 24 months, and 36 months of follow up
(Table 2). The relative risk reduction for the combined CHD/stroke
endpoint was approximately 25% in the LDL-P target cohort,
consistent across 12 months (HR: 0.76; 95% CI: 0.61e0.96), 24
months (HR: 0.78; 95% CI: 0.62e0.97), and 36 months (HR: 0.75;
95% CI: 0.58e0.97) of follow-up. Incidence rates increased over
time, from a mean number of CHD/stroke events of 0.10 (LDL-P) vs.
0.11 (LDL-C) at 12months to 0.28 vs. 0.34 at 36months. KM survival
curves at 36 months (Fig. 3) illustrate the increasing separation in
CHD/stroke events between LDL-P and LDL-C cohorts.
4. Discussion
4.1. Summary of results
This is the ﬁrst study demonstrating a real-world association
between LDL-P levels and CHD/stroke risk. The longitudinal nature
of this large database allowed for long-term assessments of up to
three years. First, we found that increases in LDL-P are signiﬁcantly
associated with higher risk of CHD events, after accounting for LDL-
C. Second, we observed that high-risk patients who achieved an
LDL-P level <1000 nmol/L (20th population percentile based on
MESA [13]) received more aggressive lipid lowering therapy and
had fewer CHD/stroke events than patients who achieved an LDL-C
level <100 mg/dL (also 20th population percentile in MESA).
Compared to the LDL-C cohort, the proportion of patients with
CHD/stroke events in the LDL-P cohort was reduced by 1.8, 2.9 and
4.4 percentage points at 12, 24 and 36 months follow-up, respec-
tively. Similarly, the number of events per patient was reduced by
9%, 27% and 18% respectively within the same timeframes.
4.2. Interpretation and future research
These results are consistent with analyses of several epidemi-
ological studies and clinical trials which have shown that cardio-
vascular events track with LDL-P [11e13]. In both the Framingham
Offspring Study [11] and MESA [13], it was shown that when LDL-C
and LDL-P were concordant (i.e., in agreement), each measure was
equally associated with CHD risk whereas when LDL-C and LDL-P
Table 1
Baseline characteristics for patients with 12 months of follow-up (LDL-P vs. LDL-C cohort matched comparisons).
LDL-P goal cohort (n ¼ 2094) LDL-C goal cohort (n ¼ 2094) p-value Standardized diff.
Age (on index date), mean (±SD) 56.93 (10.6) 56.29 (10.9) 0.055 6
Gender, n (%)
Female 899 (42.9) 881 (42.1) 0.574 2
Geographic region, n (%)
Northeast 63 (3.0) 62 (3.0) 0.928 0
Midwest 432 (20.6) 444 (21.2) 0.648 1
South 1386 (66.2) 1354 (64.7) 0.299 3
West 147 (7.0) 164 (7.8) 0.316 3
Unknown/missing 66 (3.2) 70 (3.3) 0.727 1
Types of health plan, n (%)
HMO 776 (37.1) 733 (35.0) 0.320 4
PPO 924 (44.1) 956 (45.7) 0.166 3
Other 394 (18.8) 405 (19.3) 0.736 1
Medicare advantage, n (%) 241 (11.5) 249 (11.9) 0.701 1
Comorbidities, n (%)
Hypertension 1553 (74.2) 1556 (74.3) 0.916 0
Diabetes mellitus 1183 (56.5) 1198 (57.2) 0.640 1
Cardiovascular disease 1313 (62.7) 1279 (61.1) 0.279 3
Coronary heart disease 1089 (52.0) 1051 (50.2) 0.240 4
Peripheral vascular disease 306 (14.6) 275 (13.1) 0.166 4
Stroke/transient ischemic attack 282 (13.5) 273 (13.0) 0.682 1
QuaneCharlson comorbidity index, mean (±SD) 1.04 (1.3) 1.12 (1.2) 0.043 6
Medication utilization, n (%)
Any antihypertensive medications 1382 (66.0) 1469 (70.2) 0.004 9
Any antidiabetic medications 892 (42.6) 910 (43.5) 0.574 2
Any lipid-lowering medications 1524 (72.8) 1464 (69.9) 0.040 6
Statins 1365 (65.2) 1314 (62.8) 0.101 5
Potency level 1 9 (0.4) 19 (0.9) 0.058 6
Potency level 2 62 (3.0) 87 (4.2) 0.037 6
Potency level 3 383 (18.3) 484 (23.1) <0.001 12
Potency level 4 794 (37.9) 706 (33.7) 0.005 9
Potency level 5 236 (11.3) 125 (6.0) <0.001 19
Bile acid sequestrants 41 (2.0) 19 (0.9) 0.004 9
Fibric acid derivatives 159 (7.6) 177 (8.5) 0.306 3
Intestinal cholesterol Absorption inhibitors 161 (7.7) 91 (4.4) <0.001 14
Nicotinic acid Derivatives 200 (9.6) 74 (3.5) <0.001 25
Antihyperlipidemics e combinations 97 (4.6) 75 (3.6) 0.087 5
Prescription omega 3 fatty acids 84 (4.0) 39 (1.9) <0.001 13
Antiplatelet agents 329 (15.7) 336 (16.1) 0.767 1
HDL-C ¼ high-density lipoprotein cholesterol; HDL-P ¼ high-density lipoprotein particle number; HMO ¼ health maintenance organization; LDL-C ¼ low-density lipoprotein
cholesterol; LDL-P ¼ low-density lipoprotein particle number; PPO ¼ preferred provider organization; SD ¼ standard deviation.
P-values are from chi-square tests for categorical outcomes and t-tests for continuous outcomes. Standardized difference ¼ difference in means or proportions divided by
standard error. Statin potency levels were assessed using the classiﬁcation from Chong PH: Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors. Ann
Pharmacother. 2002 Dec; 36(12):1907e17.
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syndrome), risk tracked with only LDL-P, not LDL-C. Statin trials
have demonstrated that many subjects who achieve LDL-C goals
remain at risk for CVD events [22e25]. This residual risk may be
related to persistently elevated LDL-P levels resulting from greater
lowering of LDL-C than LDL-P by statins [25]. These results suggest
that using LDL-C levels alone to guide treatment decisions may
mask the need to consider changes in lipid lowering therapy to
achieve appropriate reductions in LDL-P. These changes may
include increasing statin medication dosage, selecting a new agent,
or using a combination therapy regimen to help achieve LDL-P
control [14,15]. We selected an LDL-C target of <100 mg/dL and
an LDL-P target of <1000 nmol/L rather than the more aggressive
targets of <70 mg/dL and <700 nmol/L because there were few
patients that achieved LDL-P levels this low. Furthermore, themean
baseline LDL-C levels were already low in both cohorts (73mg/dL in
the LDL-P cohort and 79 mg/dL in the LDL-C cohort, for the 12
month cohort).
The use of LDL-P as a target of therapy in the management of
appropriate at-risk patients has been advocated by multiple expert
panels and guidelines [4,14e17]. Measurement of LDL-P continues
to be relevant in the context of the 2013 Guideline on the Treatment
of Blood Cholesterol to Reduce Atherosclerotic Risk in Adults issued
by the ACC and the American Heart Association [5]. In thisguideline, LDL lowering remains a central tenet of clinical practice;
LDL testing is used to guide clinical judgment of patient adherence
to treatment, individual response to therapy and need for adjust-
ment in medications to achieve an appropriate individual response.
This requires highly reliable LDL measures that correlate with
clinical outcomes.
The consistent reduction in risk observed in the LDL-P cohort
raises several important questions. First, what was the provider's
motivation for ordering the LDL-P test in this population of high-
risk patients? Patients achieving LDL-P levels <1000 nmol/L had
similar LDL-C levels as patients in the LDL-C cohort (between 70
and 80 mg/dL, see Appendix Table 5) but received more aggressive
lipid lowering therapy. While it seems reasonable to assume that
LDL-P information was being utilized to guide treatment selection,
no information regarding provider intent was available within the
database. It may be that those providers who order an LDL-P proﬁle
are more aggressive in their lipid management practices and more
likely to target atherogenic particles in addition to (or as well as)
LDL-C. In addition, LDL-Pmonitoring may have provided physicians
a better way to assess both the efﬁcacy of mainly statin-based lipid
lowering therapy as well as patients' adherence to therapy. A
reduction in LDL-P may provide a more sensitive measure of
response to therapy when there is a lack of further reduction in
mean LDL-C levels (Appendix Table 5).
Table 2
Event risk for matched LDL-P and LDL-C target cohorts over 12, 24, and 36 month follow-up periods.
12 months follow-up 24 months follow-up 36 months follow-up
LDL-P cohort LDL-C cohort p-value LDL-P cohort LDL-C cohort p-value LDL-P cohort LDL-C cohort p-value
N 2094 2094 1242 1242 705 705
CHD risk
1 event, n (%) 122 (5.83) 156 (7.45) 0.035 126 (10.1) 157 (12.6) 0.050 103 (14.6) 134 (19.0) 0.027
Events, mean (±SD) 0.09 (0.45) 0.10 (0.36) 0.027 0.17 (0.61) 0.22 (0.81) 0.030 0.26 (0.80) 0.29 (0.76) 0.039
HR (95% CI) 0.78 (0.61e0.98) e 0.035 0.79 (0.63e1.00) e 0.052 0.75 (0.58e0.97) e 0.029
Stroke risk
1 event, n (%) 18 (0.86) 28 (1.34) 0.138 23 (1.9) 37 (3.0) 0.067 12 (1.7) 27 (3.8) 0.015
Events, mean (±SD) 0.01 (0.12) 0.02 (0.15) 0.139 0.02 (0.18) 0.03 (0.20) 0.050 0.02 (0.16) 0.04 (0.23) 0.015
HR (95% CI) 0.64 (0.36e1.16) e 0.141 0.62 (0.37e1.04) e 0.069 0.44 (0.22e0.87) e 0.018
CHD/stroke risk
1 event, n (%) 131 (6.26) 170 (8.12) 0.020 136 (11.0) 173 (13.9) 0.025 103 (14.6) 134 (19.0) 0.027
Events, mean (±SD) 0.10 (0.50) 0.11 (0.46) 0.026 0.19 (0.70) 0.26 (0.90) 0.027 0.28 (0.86) 0.34 (0.87) 0.031
HR (95% CI) 0.76 (0.61e0.96) e 0.021 0.78 (0.62e0.97) e 0.028 0.75 (0.58e0.97) e 0.029
CHD ¼ coronary heart disease; CI ¼ conﬁdence interval; HR ¼ hazard ratio; LDL-C ¼ low-density lipoprotein cholesterol; LDL-P ¼ low-density lipoprotein particle number.
p-values are from chi-square tests for categorical outcomes and t-tests for continuous outcomes. P-values for hazard ratios are from Cox PH models.
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reduction is attributable to reduced LDL-P levels or due to the ef-
fects of higher statin doses unrelated to LDL lowering? Although
the majority of marketed lipid lowering pharmacotherapies are
targeted toward decreasing LDL burden, these drugs do have vari-
able effects on other lipid and nonlipid risk factors that could
contribute to the observed reduction in CHD/stroke risk. It is also
remarkable that among patients undergoing measurement of LDL-
P, all other components of the lipid proﬁle were signiﬁcantly better
over 12, 24, and 36 months compared to patients followed-up with
LDL-C, thus likely impacting CVD event risk. Future research may
also help to clarify whether very aggressive LDL-C lowering could
mimic the reduction in CVD event risk observed in the LDL-P
cohort; no appropriate LDL-C threshold for this approach has
been deﬁned to date.
Finally, does the improvement in clinical outcomes in patients
treatedmore aggressively in the LDL-P cohort outweigh the costs of
additional therapy? A recent study compared the cost-effectiveness
of managing patients to LDL-P goals versus management to LDL-C
goals [26]. An economic model was developed based onFig. 3. CHD/stroke event risk over 36 months e KaplaneMeier Curves for Combined CHD
LDL-P vs. LDL-C on CHD/stroke risk).parameters from published literature, including clinical data from
MESA. The results suggested that managing LDL-P, either alone or
in combination with LDL-C, reduced costs and cardiovascular
events and increased quality-adjusted life years in comparisonwith
LDL-C-only management. Further research into cost-effectiveness,
particularly in a real-world setting, is needed.
4.3. Limitations
There are some limitations in this type of analysis that are
important to describe. The study sample was taken from one large
US commercial health plan and results may not be generalizable to
patients enrolled in different plans or outside the US. Because the
study used a claims database, there was no information on race and
other risk factors (e.g., family history of CHD, smoking status, BMI,
diet, exercise, socioeconomic status) available in the dataset which
could inﬂuence outcomes. However, most of these factors may
plausibly be distributed equally across the LDL-P and LDL-C cohorts
and thus would have little effect on outcome comparisons. Also, it is
possible that the disease codes in the claims database used to/Stroke Risk at 36 months of follow-up (Part 2: Comparative Effectiveness Analysis of
P.P. Toth et al. / Atherosclerosis 235 (2014) 585e591 591identify CHD/stroke events may not correspond entirely to the true
presence of disease since codes are entered by health care pro-
viders for the purpose of insurance billing. Propensity score
matching was used to simulate randomization into treatment co-
horts based on observed characteristics; it is possible selection bias
based on unobservable variables remained. Finally, patient medi-
cation adherence to either lipid lowering drugs or other car-
dioprotective medicines was not assessed.
4.4. Conclusions
This study is the ﬁrst to investigate the association between
LDL-P and CHD/stroke events in a large-scale, real-world environ-
ment of commercially insured patients. Results suggest that (1)
there is a direct association between increases in LDL-P and the
risk of CHD events, after accounting for LDL-C levels, and (2) pa-
tients achieving an LDL-P level <1000 nmol/L received more
aggressive lipid lowering therapy than patients achieving an LDL-C
level <100 mg/dL and that these differences in lipids and thera-
peutic management were associated with signiﬁcantly better
control of all components of the standard lipid proﬁle and a
reduction in CHD/stroke events over 12, 24 and 36 months follow-
up. This suggests that visibility to LDL-P levels may aid in patient
management and result in more favorable clinical outcomes.
Further research, including a prospective clinical trial, would be
valuable to help conﬁrm these results.
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